

159. Adam Z, Král Z, Klimeš J, Boleloucký Z, Pour L. Chronický stres, psychická nepohoda a deprese zvyšují četnost infekčních, autoimunitních, ale i maligních nemocí. Vnitř. lék. 2020;66(1):34-38.
160. Adam Z, Klimeš J, Pour L, et al. Maligní onemocnění, psychika a stres: příběhy pacientů s komentářem psychologa. Praha: Grada Publishing; 2019.
161. Klimeš J, Adam Z. Dystymie – lidé s temnou duší a jejich blízcí. Novela Bohemia; 2022.
162. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone induction followed by lenalidomide and dexamethasone maintenance in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant: results of the randomised phase III SWOG trial S0777. Lancet. 2017;389:519-527.
163. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311-1320.
164. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018;32:383-390.
165. Dimopoulos MA, Moullopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037-2044.
166. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52:245-249. doi: 10.1016/S0167-8140(99)00114-0.
167. Nahi H, Genell A, Walinder G, et al. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol. 2017;99:216-222. doi: 10.1111/iej.12907.
168. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210-217. doi: 10.1016/j.ijrobp.2005.06.039.
169. Glasbey JC, Arshad F, Almond LM, et al. Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. Ann R Coll Surg Engl. 2018;100(5):371-376. doi: 10.1308/rcsann.2018.0015.
170. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:6. doi: 10.1100/2012/895765.
171. Weber DM. Solitary bone and extramedullary plasmacytoma. ASH Education Program Book. 2005;2005:373-376.
172. Boll M, Parkins E, O'Connor SJM, Rawstron AC, Owen RG. Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvement. Br J Haematol. 2010;151:525-527. doi: 10.1111/j.1365-2141.2010.08386.x.
173. Hill QA, Rawstron AC, de Tute RM, Owen RG. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124:1296-1299. doi: 10.1182/blood-2014-04-566521.
174. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;6. doi: 10.1100/2012/895765.
175. Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;16(11):10. doi: 10.1186/s13045-017-0549-1.
176. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717-726.
177. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50:113-120. doi: 10.1016/S0360-3016(00)01572-8.
178. Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101(4):794-808. doi: 10.1016/j.ijrobp.2018.05.009.
179. König L, Herfarth K. Nutzen der Radioonkologie beim solitären Plasmazytom oder multiplen Myelom [Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma]. Radiologie. 2022;62(1):30-34. German. doi:10.1007/s00117-021-00935-y.
180. Pika T, Minařík J, Prášil V, et al. Solitární kostní plazmocyto. Osteologický bulletin. 2012;17(4):136-142.
181. Bačovský J. Solitární plazmocyto Interní medicína pro praxi. 2005;7(10):444-446.
182. Hrabovský Š, Řehák Z, Stálík J, et al. Raritní případ mnohočetného myelomu: vícečetný solitární plazmocyto kostí bérů a předloktí. Vnitř. lék. 2015;61(2):161-165.
183. Pham A, Mahindra A. Solitary Plasmacytoma: a Review of Diagnosis and Management. Curr Hematol Malig Rep. 2019;14(2):63-69. doi:10.1007/s11899-019-00499-8.
184. Kyle RA, Maldonado JE, Bayrd ED, et al. Plasma cell leukemia. Report on 17 cases Arch. Intern. Med. 1974;133(5):813-818.
185. Granell M, Calvo X, Garcia-Guion, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102(6):1099-1104.
186. Ravi P, Kumar A, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma Blood Cancer J. 2018;8(12):116. doi: 10.1038/s41408-018-0140-1.
187. Fernandez de Larrea C, Kyla RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group Leukemia. 2013;27(4): pp. 780-791.
188. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. doi:10.1038/s41408-021-00587-0. PMID: 34857730.
189. Gowin K, Skerget S, Keats JJ, et al. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res. 2021;111:106687. doi: 10.1016/j.leukres.2021.106687.
190. Jung SH, Lee JJ. Update on primary plasma cell leukemia. Blood Res. 2022;57(1):62-66. doi: 10.5045/br.2022.2022033. PMID: 35483928.
191. Matýšková M, Krahulcová E, Bulíková A. Pohrudniční výpotek při plazmacelulární leukémii. Vnitř. lék. 1995;41(7):467-469.
192. Žárská M, Vrábel D, Bezděková R, et al. Plazmocelulární leukemie – zapomenutá nemoc. Klinická onkologie. 2019;32(1):40-46.
193. Kovářová L, Szeligová L, Kisořová J, et al. Stanovení diagnózy plazmocelulární leukémie v praxi. Klinická onkologie. 2008;21(Suppl.):258-260.
194. Dhakal B, Patel S, Ginius S, Bachegowda L, et al. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021;35(7):2141. doi: 10.1038/s41375-021-01304-3. Erratum for: Leukemia. 2020 Dec;34(12):3338-3347.
195. Parrondo RD, Moustafa MA, Reeder C, et al. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(5):355-360. doi:10.1016/j.clml.2021.01.002.
196. Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020;95(2):E34-E35. doi: 10.1002/ajh.25676.
197. Gonsalves WL, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis Blood. 2014;6(6):907-912.
198. Nandakumar B, Kumar SA, Dispenzieri A, et al. Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy Mayo Clin. Proc. 2021;96(3):677-687.
199. Sudo Y, Inagaki H. High-output heart failure associated with primary plasmacell leukaemia due to arteriovenous shunting: a case report. Eur Heart J Case Rep. 2021;5(9):ytab353. doi: 10.1093/ehjcr/ytb353
200. Zapletalová M, Krejčí D, Jarkovský J, et al. Epidemiology of plasma cell leukemia in the Czech Republic. Klinická onkologie. 2019;32(1):47-51.
201. Ciferská H, Vachek J. Diferenciální diagnostika bolestí zad. Vnitř. lék. 2022;68(5):332-341.